In the setting of allogeneic transplant, pure stem cell grafts could be used in place of today’s replete or modified grafts, which could lead to faster and more complete engraftment of donor stem cells without the need for toxic conditioning. In addition, by eliminating the need for donor passenger lymphocytes to drive engraftment, our eHSCs could potentially eliminate the risk of GvHD and the need for long-term immune suppression. They also have the potential to expand the number of donors available for any given patient. In the setting of autologous gene edited stem cells, our eHSCs could lead to faster and more complete engraftment of edited cells without the need for toxic conditioning.
You are now leaving the Jasper Therapeutics, Inc. site to a 3rd party website. Jasper Therapeutics is not responsible for 3rd party website content.